Skip to main content

Rheumatoid Arthritis

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today
Jan 27, 2021

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.



Compared with patients taking tumor necrosis factor (TNF) inhibitors, those assigned to tofacitinib (5

Read Article
QD Clinic Week Of 1.17.2021 Myalgias & Arthralgias, Smoking and RA, The Dastardly, nastardly facts of smoking and RA, Oivay the Elevated ESR https://t.co/hTQ46YZTzG

Dr. John Cush RheumNow ( View Tweet)

Jan 24, 2021
In the UK, NICE has recommending ed (to NHS) that filgotinib (Jyseleca) be approved for use in moderate to severe active rheumatoid arthritis (RA).https://t.co/g5zLwIa3MK

Dr. John Cush RheumNow ( View Tweet)

Jan 22, 2021
UTSW Rheum Grand Rounds - IgG4 Dz commonly presents as major salivary and lacrimal gland enlargement, orbital disease, autoimmune pancreatitis, retroperitoneal (mass) fibrosis or tubulointerstitial nephritis. @UTSWIMchief

Dr. John Cush RheumNow ( View Tweet)

Jan 21, 2021

Mortality Risk in Rheumatoid Lung Patients

Jan 20, 2021

A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks, including respiratory and cancer mortality not explained by other factors.



Sparks

Read Article
Swedish Rheumatology Quality Register study of 46316 RA pts (322601 visits) shows RA has a higher risk of venous thromboembolism (RR 1.88;95% CI 1.65, 2.15) & this increased with disease activity (RR=2.03;1.73 to 2.38) (compared to remission). https://t.co/R59tLy8WGx

Dr. John Cush RheumNow ( View Tweet)

Jan 20, 2021
Sign up to attend RheumNow Live--March 20 and 21. CME credits available https://t.co/vJlU0Z3Q3x https://t.co/Z0ectgFD2d
Dr. John Cush RheumNow ( View Tweet)
Jan 20, 2021
Pooled analysis of 16 RCTs in 7044 abatacept treated pts (21,274 PYs exposure) found very low risk of opportunistic infections ranging from OIs 0.17 to 0.21 on ABA and 0.56 on placebo - only 13 TB cases; IR for H zoster was low 1.53/100PY https://t.co/kOWYxEmQLd

Dr. John Cush RheumNow ( View Tweet)

Jan 19, 2021
RheumNow Podcast Now UP – Steroids, IVIG & the Vaccine. How to handle COVID19 Vaccine issues, IL-6 inhibition in COVID, Comorbidites in RA, IVIG in dermatomyositis, & more... https://t.co/f0wWTm2kV5

Dr. John Cush RheumNow ( View Tweet)

Jan 17, 2021
2020 Rheumatology Year in Review-- Read our top news items that rheumatologists should recollect and integrate into clinical standards for 2021 and beyond. https://t.co/QisCpdcLEa https://t.co/pZekUvcomE
Dr. John Cush RheumNow ( View Tweet)
Jan 16, 2021
Real good historic review of RA drug development wherein Dr Paul Emery interviews Dr. Mike Weinblatt - Good Listen from the Cytokine Signaling Forum podcast https://t.co/R7rg7AwVlG

Dr. John Cush RheumNow ( View Tweet)

Jan 15, 2021

2020 Rheumatology Year in Review

Jan 14, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article
2 yr Early RA cohort (CareRA) study found that RA pPatients with co-morbidities had over time lower chances of achieving remission (OR = 0.724; 95% CI: 0.604, 0.867) and a higher risk of hospitalization (OR = 3.725; 95% CI: 2.136, 6.494).https://t.co/B1um1iMSKu

Dr. John Cush RheumNow ( View Tweet)

Jan 14, 2021
Telemedicine study on accuracy of Pt reported swelling predicting inflamm arthritis. 1637 pts w/ 13 wks of Sxs. 76% pts reported swelling, but only found by 41% of Rheums. Pt reporting sensitivity was was 87%, but specificity only 31%; PPV=46%, NPV=77% https://t.co/oV3p06BHRj

Dr. John Cush RheumNow ( View Tweet)

Jan 13, 2021

Hydroxychloroquine Shortage During COVID-19

Jan 12, 2021

According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.



Despite public, political and quasi research evidence supporting

Read Article
Corticosteroid Use Hikes CV Risks in Rheumatic Patients--It is long known that high-dose steroids may increase the risk of cardiovascular disease (CVD), heart disease, stroke, or other vascular outcomes, but it is unknown what the risk is at lower doses. https://t.co/gkTLP3ceVD https://t.co/HMpvpham1q
Dr. John Cush RheumNow ( View Tweet)
Jan 12, 2021

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

Jan 11, 2021

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.

Read Article
Rheumatologists: Record your question or case for the RheumNow podcast. https://t.co/NDhYNX50e2

Dr. John Cush RheumNow ( View Tweet)

Jan 09, 2021

Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis

Jan 06, 2021

Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine. A novel trial of IV rilonacept, an IL-1 α and IL-1β cytokine trap, resulted in rapid resolution of recurrent pericarditis and to a

Read Article
Join us this March for RheumNow Live! Sign up via the link below. https://t.co/vJlU0Z3Q3x https://t.co/G1s3F7zKlI
Dr. John Cush RheumNow ( View Tweet)
Jan 05, 2021
23% of RA patients have moderate-to-severe Obstructive Sleep Apnea (AHI ≥ 15) - study of RA patients 199 patients underwent PSG, OSA is more common in RA than in the general population, but there is no relationship with disease activity. https://t.co/wNasW3AerN

Dr. John Cush RheumNow ( View Tweet)

Jan 04, 2021
ENTRACTE trial studied the risk of major adverse CV events (MACE) in 3080 RA pts Rx with tocilizumab (TCZ) vs etanercept (ETN), and found no increased risk of MACE in TCZ patients compared to ETN (HR 1.05 (95% confidence interval 0.77–1.43). https://t.co/KpOEeVAAxx

Dr. John Cush RheumNow ( View Tweet)

Jan 02, 2021
Listen to the RheumNow podcast where we look back at #ACR20 https://t.co/M3zJ0tzIPz https://t.co/zPwNtomf1K
Dr. John Cush RheumNow ( View Tweet)
Dec 30, 2020
Red Flags and Detours -- New RA Guidelines: Dr. Jack Cush dons his bullet-proof vest before taking aim at the new ACR RA Guidelines at presented at #ACR20. https://t.co/ZhfCiP59Qu https://t.co/0VUczI7pXu
Dr. John Cush RheumNow ( View Tweet)
Dec 30, 2020
Download our document titled "Difficult RA Defined" https://t.co/6WGMEiwiUk https://t.co/FFoAn08tjC
Dr. John Cush RheumNow ( View Tweet)
Dec 30, 2020
×